文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

比较Ⅰ-Ⅱ期乳腺癌患者接受前哨淋巴结活检、前哨淋巴结活检后行淋巴结清扫术与腋窝淋巴结清扫术的手臂发病率的纵向研究。

A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection.

机构信息

Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

Ann Surg Oncol. 2010 Sep;17(9):2384-94. doi: 10.1245/s10434-010-0981-8. Epub 2010 Mar 11.


DOI:10.1245/s10434-010-0981-8
PMID:20221902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2924495/
Abstract

BACKGROUND: Long-term shoulder and arm function following sentinel lymph node biopsy (SLNB) may surpass that following complete axillary lymph node dissection (CLND) or axillary lymph node dissection (ALND). We objectively examined the morbidity and compared outcomes after SLNB, SLNB + CLND, and ALND in stage I/II breast cancer patients. MATERIALS AND METHODS: Breast cancer patients who had SLNB (n = 51), SLNB + CLND (n = 55), and ALND (n = 65) were physically examined 1 day before surgery (T0), and after 6 (T1), 26 (T2), 52 (T3), and 104 (T4) weeks. Differences in 8 parameters between the affected and unaffected arms were calculated. General linear models were computed to examine time, group, and interaction effects. RESULTS: All outcomes changed significantly, mostly nonlinearly, over time (T0-T4). Between T1 and T4, limitations decreased in abduction (all groups); anteflexion, abduction-exorotation, abduction strength (SLNB + CLND, ALND); flexion strength (SLNB + CLND); and arm volume (SLNB, SLNB + CLND). At T4, limitations in anteflexion (SLNB, ALND), abduction (SLNB + CLND, ALND), exorotation (ALND), abduction-exorotation (all groups), and volume (SLNB + CLND, ALND) increased significantly compared with T0. The SLNB group showed an advantage in anteflexion, abduction, abduction-exorotation, and volume. Groups changed significantly but differently over time in anteflexion, abduction, abduction/exorotation, abduction strength, flexion strength, and volume. Effect sizes varied from 0.19 to 0.00. CONCLUSION: Initial declines in range of motion and strength were followed by recovery, although not always to presurgery levels. Range of motion and volume outcomes were better for SLNB than ALND, but not strength. SLNB surpassed SLNB + CLND in 2 of the range of motion variables. The clinical relevance of these results is negligible.

摘要

背景:前哨淋巴结活检(SLNB)后的肩部和手臂功能长期预后可能优于完全腋窝淋巴结清扫术(CLND)或腋窝淋巴结清扫术(ALND)。我们客观地检查了发病率,并比较了 I/II 期乳腺癌患者 SLNB、SLNB+CLND 和 ALND 后的结果。

材料和方法:接受 SLNB(n=51)、SLNB+CLND(n=55)和 ALND(n=65)的乳腺癌患者在手术前 1 天(T0)、术后 6 周(T1)、26 周(T2)、52 周(T3)和 104 周(T4)进行体格检查。计算受影响和未受影响手臂之间 8 个参数的差异。使用通用线性模型来检查时间、组和交互作用的影响。

结果:所有结果均随时间显著变化(T0-T4),主要呈非线性变化。在 T1 到 T4 之间,外展(所有组);前屈、外展-外旋、外展力量(SLNB+CLND、ALND);屈曲力量(SLNB+CLND);和手臂体积(SLNB、SLNB+CLND)减少。在 T4 时,与 T0 相比,前屈(SLNB、ALND)、外展(SLNB+CLND、ALND)、外旋(ALND)、外展-外旋(所有组)和体积(SLNB+CLND、ALND)的受限明显增加。与 SLNB+CLND 和 ALND 相比,SLNB 组在前屈、外展、外展-外旋和体积方面具有优势。各组在 T0 时的前屈、外展、外展-外旋、外展力量、屈曲力量和体积变化明显,但方式不同。效应大小从 0.19 到 0.00 不等。

结论:运动范围和力量最初下降,随后恢复,但并非总是恢复到术前水平。与 ALND 相比,SLNB 在运动范围和体积方面优于 ALND,但在力量方面并非如此。在 2 个运动变量中,SLNB 优于 SLNB+CLND。这些结果的临床意义可以忽略不计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecf0/2924495/2d7021320d0c/10434_2010_981_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecf0/2924495/19413470d7a5/10434_2010_981_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecf0/2924495/efa5bc8cbbc8/10434_2010_981_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecf0/2924495/2d7021320d0c/10434_2010_981_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecf0/2924495/19413470d7a5/10434_2010_981_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecf0/2924495/efa5bc8cbbc8/10434_2010_981_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecf0/2924495/2d7021320d0c/10434_2010_981_Fig3_HTML.jpg

相似文献

[1]
A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection.

Ann Surg Oncol. 2010-3-11

[2]
Quality of life after sentinel lymph node biopsy or axillary lymph node dissection in stage I/II breast cancer patients: a prospective longitudinal study.

Ann Surg Oncol. 2008-9

[3]
A longitudinal study of shoulder and arm morbidity in breast cancer survivors 7 years after sentinel lymph node biopsy or axillary lymph node dissection.

Breast Cancer Res Treat. 2013-4-16

[4]
Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.

J Surg Oncol. 2006-2-1

[5]
Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer.

Ann Surg Oncol. 2004-11

[6]
Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma.

Cancer. 2003-8-15

[7]
Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients.

Br J Cancer. 2003-8-18

[8]
Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer.

Ann Surg Oncol. 2008-7

[9]
Prospective study of shoulder strength, shoulder range of motion, and lymphedema in breast cancer patients from pre-surgery to 5 years after ALND or SLNB.

Support Care Cancer. 2018-4-12

[10]
Arm morbidity of axillary dissection with sentinel node biopsy versus delayed axillary dissection.

ANZ J Surg. 2018-9

引用本文的文献

[1]
Breaking Dogmas in Axillary Lymphadenectomy and Quality of Life.

Cancers (Basel). 2025-6-30

[2]
A comparative study of dual-layer spectral CT and 18F-FDG-PET/CT multi-quantitative parameters in the diagnosis of sentinel lymph nodes in breast cancer.

Ann Nucl Med. 2025-6-17

[3]
Multimodal AI model for preoperative prediction of axillary lymph node metastasis in breast cancer using whole slide images.

NPJ Precis Oncol. 2025-5-6

[4]
A nomogram model for predicting the risk of axillary lymph node metastasis in patients with early breast cancer and cN0 status.

Oncol Lett. 2024-5-30

[5]
Comparison of Intraoperative Imprint Cytology versus Frozen Section for Sentinel Lymph Node Evaluation in Breast Cancer. A study along with Systematic Review and Meta-analysis of literature.

Asian Pac J Cancer Prev. 2024-4-1

[6]
Immediate Lymphatic Reconstruction with Vascularized Omentum Lymph Node Transplant: Reducing the Risk of Both Painful Contracture and Lymphedema.

Plast Reconstr Surg Glob Open. 2024-4-19

[7]
Upper Limb Morbidity in Newly Diagnosed Individuals After Unilateral Surgery for Breast Cancer: Baseline Results from the AMBER Cohort Study.

Ann Surg Oncol. 2023-12

[8]
Can inflammatory indices predict sentinel lymph node status in patients with early-stage breast cancer?

Medicine (Baltimore). 2023-8-18

[9]
The application of contrast-enhanced ultrasound for sentinel lymph node evaluation and mapping in breast cancer patients.

Quant Imaging Med Surg. 2023-7-1

[10]
Comparative Analysis of Postoperative Complications of Sentinel Node Identification Using the SentiMag Method and the Use of a Radiotracer in Patients with Breast Cancer.

Curr Oncol. 2022-4-19

本文引用的文献

[1]
Cancer statistics, 2009.

CA Cancer J Clin. 2009

[2]
Late morbidity associated with a tumour-negative sentinel lymph node biopsy in primary breast cancer patients: a systematic review.

Eur J Cancer. 2009-6

[3]
Quality of life after sentinel lymph node biopsy or axillary lymph node dissection in stage I/II breast cancer patients: a prospective longitudinal study.

Ann Surg Oncol. 2008-9

[4]
Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer.

Ann Surg Oncol. 2008-7

[5]
A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.

Ann Surg. 2008-2

[6]
Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group.

Breast. 2008-4

[7]
Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.

Ann Surg Oncol. 2008-1

[8]
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.

Lancet Oncol. 2007-10

[9]
Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.

Eur J Surg Oncol. 2008-5

[10]
Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients.

Ann Surg. 2007-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索